Stocks React To February Jobs Report: The Winners And Losers
The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors.
FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting
Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…
AstraZenceca’s Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…
AstraZeneca’s Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
In a trial, lung cancer patients treated with AstraZeneca plc’s (NASDAQ:AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the…
Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
Medtronic Says PulseSelect Ablation System Demonstrates ‘Impressive Results’
Medtronic plc (NYSE:MDT) announced that its PulseSelect Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse…
How Much Of Nvidia’s Stock Do You Need To Yield $200 Per Month?
Shares of Nvidia Corporation (NASDAQ: NVDA), a leading GPU company, has been on a roll in the past six months, climbing more than 110% from November lows, with 66% of those gains given to investors in 2023 alone.
Intel Business Model ‘Structurally Misaligned With Industry Direction,’ Analyst Says
Intel Corporation (NASDAQ: INTC) is facing a tough challenge as its business model is said to be "structurally misaligned with industry direction," according to a bearish note issued Sunday by Bank of America Global Securities.
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer’s Treatment
The FDA has accepted Eisai Co Ltd (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection,…
Data Shows Abbott’s TriClip System Superior To Other Medical Therapy In Heart Valve Disorder
Abbott Laboratories (NYSE:ABT) announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a minimally invasive device designed specifically for…